Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.

Gao, H; Lee, B-N; Talpaz, M; Donato, N J; Cortes, J E; Kantarjian, H M; Reuben, J M

Gao, H; Lee, B-N; Talpaz, M; Donato, N J; Cortes, J E; Kantarjian, H M; Reuben, J M.

Affiliation

Gao H; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Leukemia ; 19(11): 1905-11, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16151467

Subject(s)

Antineoplastic Agents/pharmacology; CD4-Positive T-Lymphocytes/drug effects; Cytokines/biosynthesis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology; Piperazines/pharmacology; Pyrimidines/pharmacology; Benzamides; CD4-Positive T-Lymphocytes/physiology; Case-Control Studies; Cell Culture Techniques; Cell Proliferation/drug effects; Enterotoxins/pharmacology; Humans; Imatinib Mesylate; Lymphocyte Activation; Phosphorylation; Protein-Tyrosine Kinases/metabolism; Tyrosine; ZAP-70 Protein-Tyrosine Kinase

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / CD4-Positive T-Lymphocytes / Cytokines / Antineoplastic Agents Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2005 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links